Development of CD39 as a therapy for stroke

The brain is detrimentally affected after stroke and cardiac arrest. The aim of this thesis was to demonstrate that the novel drug from our lab - αVCAM-CD39 will improve neurological outcome in mouse models of stroke and cardiac arrest. We found that post- αVCAM-CD39 treatment, there was significant protection in the brain, and we showed that our compound was able to significantly reduced stroke-related injury, such as reduced tissue damage and cell death. We were able to confirm that αVCAM-CD39 could be a new avenue of stroke therapy and could potentially be used in other similar diseases.